TY - JOUR T1 - A Classification Approach for Predicting COVID-19 Patient’s Survival Outcome with Machine Learning Techniques JF - medRxiv DO - 10.1101/2020.08.02.20129767 SP - 2020.08.02.20129767 AU - Abdulhameed Ado Osi AU - Mannir Abdu AU - Usman Muhammad AU - Auwalu Ibrahim AU - Lawan Adamu Isma’il AU - Ahmad Abubakar Suleiman AU - Hasssan Sarki Abdulkadir AU - Safiya Sani Sada AU - Hussaini Garba Dikko AU - Muftahu Zubairu Ringim Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/10/2020.08.02.20129767.abstract N2 - COVID-19 is an infectious disease discovered after the outbreak began in Wuhan, China, in December 2019. COVID-19 is still becoming an increasing global threat to public health. The virus has been escalated to many countries across the globe. This paper analyzed and compared the performance of three different supervised machine learning techniques; Linear Discriminant Analysis (LDA), Random Forest (RF), and Support Vector Machine (SVM) on COVID-19 dataset. The best level of accuracy between these three algorithms was determined by comparison of some metrics for assessing predictive performance such as accuracy, sensitivity, specificity, F-score, Kappa index, and ROC. From the analysis results, RF was found to be the best algorithm with 100% prediction accuracy in comparison with LDA and SVM with 95.2% and 90.9% respectively. Our analysis shows that out of these three classification models RF predicts COVID-19 patient’s survival outcome with the highest accuracy. Chi-square test reveals that all the seven features except sex were significantly correlated with the COVID-19 patient’s outcome (P-value < 0.005). Therefore, RF was recommended for COVID-19 patient’s outcome prediction that will help in early identification of possible sensitive cases for quick provision of quality health care, support and supervision.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the General Research Ethics Committee of the Kano University of Science and Technology, Wudil, Nigeria. The data used in this study was obtained from various governmental agencies, compiled, de-identified and made it available by Dr. Bharatendra Rai, Director, Master of Science Technology Management Program and Chair, Dept. of Decision & Info Sciences at UMass Dartmouth.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used was extracted from https://drive.google.com/file/d/1bYcMAd-lOiSlOVGl5qxG1Sq1auyzmWHZ/view, obtained from various government agencies and compiled by Dr. Bharatendra Rai, Director, Master of Science Technology Management Program and Chair, Dept. of Decision & Info Sciences at UMass Dartmouth. https://drive.google.com/file/d/1bYcMAd-lOiSlOVGl5qxG1Sq1auyzmWHZ/view ER -